Oncology development

What 12 Pharma and Biotech Updates Mean for Clinical Trial Teams

Twelve pharma and biotech updates, including what Genmab’s LiGeR-HN1 results mean for PD-L1 screening, oncology site activation and survival follow-up.

By Lampgen Clinical Research

Gloved hands place a pathology slide case in a padded shipping box. The cover reads “Who owns the handoff?” and “Tissue testing and follow-up in oncology trials.”
Editorial illustration of a pathology specimen handoff.

5 min read · estimated

Sources
0.50 hazard ratioFirst interim analysis
Overall survival in LiGeR-HN1, comparing petosemtamab plus pembrolizumab with pembrolizumab alone

What the source reported

Genmab’s first interim Phase 3 readout supports further evaluation of a potential chemotherapy-free combination in first-line PD-L1-positive recurrent or metastatic head and neck cancer. For trial teams, the result raises a practical question about who can complete biomarker screening in time to enroll and how sites can keep follow-up reliable when patients change providers. This November 6 roundup examines that result alongside eleven other developments in clinical research, financing and public health.

Genmab reported that the randomized, open-label Phase 3 LiGeR-HN1 trial met both primary endpoints at its first interim analysis. The trial compared investigational petosemtamab, an EGFR×LGR5 bispecific antibody, plus pembrolizumab with pembrolizumab alone in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. The overall survival hazard ratio was 0.50 (95% CI 0.37–0.67), and the odds ratio for objective response was 3.17 (95% CI 2.06–4.89). The 0.50 hazard ratio represents a 50% lower estimated hazard of death with the combination at this analysis. Median survival by arm, longer follow-up and detailed adverse-event rates will help quantify benefit and risk. Genmab reported no new safety signals in the topline disclosure. [1, 2]

Lilly’s October 28 topline results came from TRANSCEND-T2D-2, a randomized, open-label Phase 3 trial in 1,298 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. Under Lilly’s efficacy estimand at week 80, the 12 mg dose of investigational retatrutide lowered A1c by 2.2 percentage points and body weight by 20.9%, compared with 1.8 points and 9.4% on semaglutide 2 mg. Adverse-event discontinuation was 7.9% versus 2.7%. Direct comparison helps put potential benefit in context, and treatment persistence belongs in the same discussion. [3]

Disc Medicine’s Phase 3 APOLLO trial randomized 183 people aged 12 and older with erythropoietic or X-linked protoporphyria to investigational bitopertin or placebo. On October 19, Disc reported that the drug reduced whole-blood protoporphyrin IX (PPIX) and added an average of 12.2 hours in light without pain during month six versus placebo. Dizziness occurred in 50% of the bitopertin group. Disc described it as mild or moderate and generally transient. In February, FDA had asked for efficacy data on a clinical endpoint after earlier trials left the relationship between PPIX and light tolerance uncertain. APOLLO measured both outcomes. On November 5, Disc reiterated plans to resubmit its application by year-end. The full results can show how the extra time was distributed across participants and days. [4, 5, 19]

Mayo Clinic researchers’ April paper in Gut evaluated REDMOD on historical abdominal CT scans. In an independent test set of 493 scans, the model had 73% sensitivity for visually occult pancreatic ductal adenocarcinoma, with a median lead time of 475 days. Specificity was 81.3% in a separate multi-institutional cohort. Prospective validation in high-risk populations needs to establish how alerts affect diagnostic workups, time to treatment and the burden of false positives. [6]

Bristol Myers Squibb disclosed on October 23 that a participant died of septic pneumonia 44 days after receiving investigational zola-cel in a Phase 1 multiple sclerosis trial. The death occurred after the interim analysis cutoff and one day after high-dose cyclophosphamide. The timing describes the clinical course. Attribution requires a separate assessment. The case underscores why late events, concomitant interventions and post-cutoff safety information must reach the same reviewers. [7]

Funding and commercial results showed different kinds of momentum. Dren Bio closed a $350 million financing on October 29 to support investigational dibotatug for rare blood cancers and other indications, plus its broader pipeline. Aspen Neuroscience closed its initial public offering on November 2 with approximately $140.6 million in gross proceeds as it develops autologous cell therapy for Parkinson’s disease. Kiniksa reported Q3 ARCALYST net product revenue of $286 million, about 58% higher year over year, and raised its 2026 product revenue guidance to $1.045–$1.050 billion. These updates describe financing and sales. Development plans still depend on program milestones and clinical evidence. [8, 9, 10]

Three proposed transactions add distinct development programs. Merck KGaA, Darmstadt, Germany, agreed to buy RNA interference developer Silence Therapeutics at about $1.3 billion in equity value ($1.1 billion in enterprise value). Gilead agreed to acquire PepStar’s oral IL-23 receptor inhibitor program, including investigational HCXT-2001 for inflammatory bowel disease, for $1.275 billion in upfront cash payable at closing, subject to customary adjustments. Ferring agreed to acquire Gameto, whose Fertilo technology is designed to mature eggs outside the body, for up to $1.3825 billion tied to development, regulatory and commercial milestones. Each announcement has its own transaction structure and closing conditions. [11, 12, 13]

In public health, WHO reported sustained Bundibugyo Ebola transmission in the Democratic Republic of the Congo and imported cases in Kenya and Nigeria in its October 23 update. CDC’s November 1 snapshot also recorded cases earlier in the outbreak in Uganda and France, where CDC reported no active cases at that cutoff. Distinguishing sustained transmission from imported cases and associated contact clusters helps public health teams target surveillance and response. [14, 15]

What this means for trial teams

Rehearse a referral before opening a site. Walk through an example from a community practice. Identify who requests outside tissue, who checks specimen adequacy and PD-L1 testing turnaround, and who confirms that the eligibility review is complete. Track time from request to result and why referrals end before screening. Review those measures by referral source to find where patients encounter delays.

Assign safety and follow-up responsibilities. Have the coordinator and infusion team rehearse an after-hours escalation to the investigator and sponsor safety team. Check who records symptom onset, interventions and follow-up. Identify who handles protocol-specified vital-status follow-up when treatment ends or care transfers, within the scope of consent. These are examples of how risk-based monitoring can focus on participant safety and the reliability of survival data. [16]

Evaluate candidates against the work. An oncology CRA should be able to trace the PD-L1 result to the source record, flag a delay that puts a screening window at risk and verify that the site resolved it. A CTM should be able to compare turnaround and screen-failure patterns across sites and decide where added coverage would help. At Lampgen, we assess those scenarios in the context of the sponsor or CRO’s protocol and site mix. [17]

Sources

  1. Genmab, LiGeR-HN1 first interim Phase 3 results, October 28, 2026
  2. ClinicalTrials.gov, LiGeR-HN1, NCT06525220
  3. Eli Lilly, TRANSCEND-T2D-2 Phase 3 topline results, October 28, 2026
  4. Disc Medicine, APOLLO Phase 3 topline results, October 19, 2026
  5. Disc Medicine, Q3 2026 update, November 5, 2026
  6. Mukherjee et al., Gut, REDMOD retrospective validation, April 2026
  7. Bristol Myers Squibb, Breakfree-2 Phase 1 results and safety update, October 23, 2026
  8. Dren Bio, $350 million private financing, October 29, 2026
  9. Aspen Neuroscience, Form 8-K on IPO close, November 2, 2026
  10. Kiniksa Pharmaceuticals, Q3 2026 results, October 27, 2026
  11. Silence Therapeutics, proposed Merck KGaA acquisition, October 19, 2026
  12. Gilead, agreement for PepStar’s oral IL-23R inhibitor program
  13. Gameto and Ferring, proposed acquisition, October 27, 2026
  14. WHO, Bundibugyo virus disease outbreak update, October 23, 2026
  15. CDC, Ebola outbreak situation summary, November 1, 2026 data cutoff
  16. FDA, ICH E6(R3) Good Clinical Practice guidance
  17. Lampgen Clinical Research, oncology CRA staffing
  18. Related Lampgen analysis on zola-cel and patient safety
  19. FDA, complete response letter for bitopertin, February 13, 2026

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?